Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance
NCT ID: NCT01141504
Last Updated: 2012-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2010-06-30
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout
NCT02093611
Effect of PeakATP on Mood, Reaction Time and Cognition
NCT05100589
Impact of Nutritional Supplementation on Aerobic Performance and Fatigue
NCT02134756
The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults
NCT07231783
Influence of Caffeinated and Non-caffeinated Pre-workout Supplements on Resistance Exercise Performance
NCT04712578
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Oral placebo capsules similar in color and size to the intervention
Placebo
Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
PeakATP 250
Oral supplement capsules containing 250 mg/day of PeakATP
PeakATP 250
The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
PeakATP 400
Oral supplement capsules containing 400 mg/day of PeakATP
PeakATP 400
The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
PeakATP 400 plus proprietary blend
Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend
PeakATP 400 plus proprietary blend
The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PeakATP 250
The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
Placebo
Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
PeakATP 400
The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
PeakATP 400 plus proprietary blend
The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to perform fatigue testing procedures;
* Not currently taking prescription medications;
* Not currently taking dietary supplements (a daily multi-vitamin not exceeding RDA is permitted)
Exclusion Criteria
* Not able to perform fatigue testing;
* Taking prescription medications;
* Taking a dietary supplement other than a multi-vitamin not exceeding RDA
20 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iowa State University
OTHER
Metabolic Technologies Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John A Rathmacher, PhD
Role: PRINCIPAL_INVESTIGATOR
Metabolic Technologies Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Iowa State University
Ames, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MTI2010-CS01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.